{"id":"W4210879173","doi":"10.1007/s10549-021-06449-4","title":"Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial","year":2022,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"Boehringer Ingelheim","keywords":"Vinorelbine; Medicine; Afatinib; Lapatinib; Internal medicine; Oncology; Trastuzumab; Breast cancer; Metastatic breast cancer; Clinical endpoint; Rash; Cancer; Chemotherapy; Clinical trial; Gefitinib; Epidermal growth factor receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001241784,0.001097843,0.001484824,0.0002842704,0.0003311264,0.0006972147,0.0005234607,0.00097277,0.002531452],"category_scores_gemma":[0.0007825676,0.0004571851,0.001051397,0.0002975837,0.000655034,0.0007804065,0.0002677385,0.001674041,0.0004943577],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006288991,"about_ca_system_score_gemma":0.0007737598,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004507036,"about_ca_topic_score_gemma":0.00133379,"domain_scores_codex":[0.9995785,0.0002111276,0.00003689372,0.00007365944,0.00003099022,0.00006870977],"domain_scores_gemma":[0.9994907,0.00008903737,0.00009614748,0.00003386869,0.00002566877,0.000264547],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8261135,0.05409622,0.01979346,0.0005774166,0.001648478,0.000261408,0.0002856419,0.001505083,0.02377061,0.0001718482,0.002322488,0.06945379],"study_design_scores_gemma":[0.632484,0.3344015,0.02673697,0.00003009811,0.000547655,0.0002762236,0.00007057677,0.001118315,0.002339554,0.0001235332,0.001841604,0.00003003274],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9968441,0.001330239,0.0001113263,0.0002112312,0.0000487082,0.0005308205,0.0002525696,0.00001688387,0.0006542239],"genre_scores_gemma":[0.9967481,0.0008081511,0.0003287416,0.0002976344,0.000137082,0.0004552026,0.0004983341,0.000004660865,0.0007221299],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002531452,"threshold_uncertainty_score":0.008468509,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07544896408578985,"score_gpt":0.4259875661619342,"score_spread":0.3505386020761443,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}